TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Arctic Bioscience AS ( (DE:9TD) ) just unveiled an announcement.
Arctic Bioscience’s recent analysis from the HeROPA study indicates that their drug candidate, HRO350, shows significant promise in reducing systemic inflammation in patients with mild to moderate psoriasis. The findings suggest that HRO350 not only improves skin symptoms and quality of life but also holds potential for broader anti-inflammatory applications, positioning it as a promising treatment option in the market. The company plans to leverage these results in commercial discussions with potential partners, highlighting the drug’s safety and efficacy.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on unique bioactive marine raw materials. The company is focused on developing HRO350, a new oral drug candidate for treating mild-to-moderate psoriasis, and sells dietary supplements globally under the brand ROMEGA®.
Average Trading Volume: 72,149
Current Market Cap: NOK89.98M
See more insights into 9TD stock on TipRanks’ Stock Analysis page.